



## Olema Oncology to Participate in Upcoming Investor Conferences

February 3, 2025

SAN FRANCISCO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- [Olema Pharmaceuticals, Inc.](#) ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that management will participate in the following investor conferences:

### **Oppenheimer 35<sup>th</sup> Annual Healthcare Life Sciences Conference**

Date: Wednesday, February 12, 2025 at 9:20 a.m. ET

Format: Virtual Presentation

### **Citi's 2025 Virtual Oncology Leadership Summit**

Date: Thursday, February 20, 2025 at 10 a.m. ET

Format: Virtual Fireside Chat

Live webcasts of these presentations will be available in the Events and Presentations section of Olema's investor relations website at [ir.olema.com](http://ir.olema.com). The webcasts will be archived for at least 30 days.

### **About Olema Oncology**

Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco, California and has operations in Cambridge, Massachusetts. For more information, please visit [www.olema.com](http://www.olema.com).

### **Media and Investor Relations Contact**

Courtney O'Konek

Vice President, Corporate Communications

Olema Oncology

[media@olema.com](mailto:media@olema.com)